Author:
Liu Su-Hsun,Virgili Gianni
Funder
U.S. Department of Health & Human Services | NIH | National Eye Institute
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257–93.
2. Ferris FLI, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–2.
3. Solomon SD, Lindsley KB, Vedula SS, Krzystlik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3(Mar):CD005139.
4. Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Philips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2022;37:6–16.
5. Bressler NM, Kaiser PK, Do DV, Nguyen QD, Park KH, Woo SJ, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review. (1879-3304 (Electronic)).